Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer. [Review]

MedStar author(s):
Citation: Frontiers in Oncology. 12:860848, 2022.PMID: 35433457Department: MedStar Georgetown University Hospital/MedStar Washington Hospital Center | Radiation Oncology ResidencyForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2022ISSN:
  • 2234-943X
Name of journal: Frontiers in oncologyAbstract: In this review we outline the current evidence for the use of hydrogel rectal spacers in the treatment paradigm for prostate cancer with external beam radiation therapy. We review their development, summarize clinical evidence, risk of adverse events, best practices for placement, treatment planning considerations and finally we outline a framework and rationale for the utilization of rectal spacers when treating unfavorable risk prostate cancer with dose escalated Stereotactic Body Radiation Therapy (SBRT). Copyright © 2022 Repka, Creswell, Lischalk, Carrasquilla, Forsthoefel, Lee, Lei, Aghdam, Kataria, Obayomi-Davies, Collins, Suy, Hankins and Collins.All authors: Aghdam N, Carrasquilla M, Collins BT, Collins SP, Creswell M, Forsthoefel M, Hankins RA, Kataria S, Lee J, Lei S, Lischalk JW, Obayomi-Davies O, Repka MC, Suy SFiscal year: FY2022Digital Object Identifier: Date added to catalog: 2022-05-11
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 35433457 Available 35433457

In this review we outline the current evidence for the use of hydrogel rectal spacers in the treatment paradigm for prostate cancer with external beam radiation therapy. We review their development, summarize clinical evidence, risk of adverse events, best practices for placement, treatment planning considerations and finally we outline a framework and rationale for the utilization of rectal spacers when treating unfavorable risk prostate cancer with dose escalated Stereotactic Body Radiation Therapy (SBRT). Copyright © 2022 Repka, Creswell, Lischalk, Carrasquilla, Forsthoefel, Lee, Lei, Aghdam, Kataria, Obayomi-Davies, Collins, Suy, Hankins and Collins.

English

Powered by Koha